Company intelligence / Profile preview
NewLimit
South San Francisco, California, United Statesnewlimit.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NewLimit has developed an mRNA-based therapeutic delivered via lipid nanoparticles targeting hepatocytes in the liver. Their lead program aims to restore youthful function in aged liver cells by delivering transcription factors that reset epigenetic age. The company has completed large-scale screens in human T cells and improved its delivery technology over time. No clinical results yet; first-in-human trials are planned within a few years, starting with alcohol-related liver disease as an initial indication before expanding to broader metabolic and age-associated conditions.
- Therapeutic areas
- GastroenterologyMetabolic Disorders
- Modalities
- mRNA-based drugsLipid nanoparticle delivery therapyEpigenetic reprogramming therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on NewLimit.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NewLimit.